Muhammed Yasir Demirci

Muhammed Yasir Demirci

Auto-generated profile, based on publicly available information

Muhammed Yasir Demirci

Department of Clinical Pharmacy, Faculty of Pharmacy, Marmara University, Maltepe, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
BOBetul Okuyan
Betul Okuyan
MBMuhammed Yunus Bektay
Muhammed Yunus Bektay
MDMuhammed Yasir Demirci
Muhammed Yasir Demirci
PAPınar Ay
Pınar Ay
MSMesut Sancar
Mesut Sancar

1 April 2024 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
DÜDuygu Ünder
Duygu Ünder
CECüneyd Enver
Cüneyd Enver
MDMuhammed Yasir Demi̇rCi̇
Muhammed Yasir Demi̇rCi̇
YAYunus Emre emre Ayhan
Yunus Emre emre Ayhan
BÖBetül Özgan
Betül Özgan
MSMesut Sancar
Mesut Sancar
Objectives: Drug -related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist -led medication review in hospitalized probable patients with coronavirus disease -2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in T & uuml;rkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician's acceptance rate of clinical pharmacists' recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug -related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.

7 April 2026 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
MDMuhammed Yasir Demirci
Muhammed Yasir Demirci
BMBulent Mutlu
Bulent Mutlu
MSMesut Sancar
Mesut Sancar
BOBetul Okuyan
Betul Okuyan
Introduction: Medication non-adherence is common in patients with acute coronary syndrome (ACS) and may increase the risk of cardiac readmissions and mortality. Aim: To evaluate the effect of a clinical pharmacist-led, behavioural theory-based discharge service designed to promote medication adherence on 30-day cardiac readmissions (primary outcome) and on clinical, humanistic, and healthcare utilisation outcomes over 360 days in patients with ACS. Method: In this single-centre, parallel-group randomised controlled trial, adult patients hospitalised with ACS were assigned by permuted block randomisation (block size 8) to the intervention or control group. The intervention comprised a clinical pharmacist-led, behavioural theory-based discharge service to promote medication adherence. The intervention consisted of medication reconciliation, medication review and patient counselling based on components of the behaviour change technique taxonomy and Health Belief Model. The primary outcome was 30-day hospital readmission for cardiac reasons. Secondary outcomes included all-cause and cardiac readmissions, emergency department visits, all-cause and cardiac mortality, medication adherence, LDL (low-density lipoprotein) target attainment, and quality of life over 360 days. Results: A total of 167 patients were analysed (intervention: n = 80; control: n = 87). The primary outcome occurred in 0/80 (0.0%) in the intervention group versus 5/87 (5.7%) in the control group (risk difference − 5.7%, 95% CI − 12.8 to 2.1%; p >0.050). Over 360 days, the control group had higher adjusted odds of cardiac readmission (aOR 4.4; 95% CI 1.2–16.0; p = 0.027), all-cause readmission (aOR 3.7; 95% CI 1.1–11.7; p = 0.029), and non-adherence at 30 days (aOR 2.4; 95% CI 1.1–5.2; p = 0.028). At 180 days, the control group had lower adjusted odds of LDL target attainment (aOR 0.4; 95% CI 0.2–0.9; p = 0.038). Conclusion: This intervention reduced 30-day cardiac readmission, but the effect was not statistically significant. According to findings of secondary outcomes, this behavioural theory-based discharge service at discharge might be effective in reducing healthcare utilisation in the long term and improving the short-term target for medication adherence in patients with acute coronary syndrome. Trial registration: ClinicalTrials.gov NCT05153707.